This bill establishes a new federal regulatory framework specifically for homeopathic drug products. Currently, homeopathic drugs are regulated under general drug rules, but this legislation creates a distinct category with tailored requirements that account for their unique preparation methods and historical use. The bill exempts homeopathic products from the standard drug approval process while requiring them to meet specific safety, quality, and manufacturing standards set by the FDA within three years. Manufacturers must ensure safety in intermediate preparations containing potentially harmful substances and label products clearly with the statement that uses have not been FDA-evaluated and are based on traditional homeopathic practice. The bill also establishes a Homeopathic Drug Product Advisory Committee to advise the FDA on regulation, consisting of practitioners, manufacturers, educators, and consumer representatives, and it prevents dietary supplements, non-homeopathic drugs, and cosmetics from falsely labeling themselves as homeopathic. The legislation repeals the FDA's 2022 guidance on homeopathic products, effectively reversing that stricter regulatory approach.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.